Skip to main content

Table 5 Best overall response to ASP3026 in the dose-expansion cohort

From: First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

Parameter Expansion cohort ASP3026 525 mg (n = 16)
Best overall responsea, n (%)  
 Complete response 0
 Partial response 8 (50)
 Stable disease 7 (44)
 Progressive disease 0
 Unable to evaluate 1 (6)
Objective response (complete response + partial response)  
n (%) 8 (50)
 95 % CIb 25–75 %
  1. CI confidence interval
  2. aBased on RECIST guidelines (v1.1) and International Working Group revised response criteria
  3. bExact CI obtained using Clopper–Pearson method